News • Anticoagulants vs coronavirus

Preventive blood thinning could reduce risk of Covid-19 death

Patients given preventive blood thinning drugs (prophylactic anticoagulants) within 24 hours of admission to hospital with Covid-19 are less likely to die compared with those who do not receive them, a new study finds.

Clinical trials are now underway to see if prophylactic anticoagulants could be an effective treatment for Covid-19. In the meantime, the researchers say these findings provide strong real world evidence to support their early use among patients in hospital with Covid-19.

The study was published in The BMJ.

Photo

Image source: Crystal Blair from Pixabay

Some covid deaths are believed to be due to blood clots developing in major veins and arteries. Anticoagulants prevent blood clots forming and have antiviral and potentially anti-inflammatory properties, so might be particularly effective in patients with Covid-19, but results from previous studies have been inconclusive. To explore this further, a team of UK and US researchers set out to estimate the effect of prophylactic anticoagulants when given promptly after admission to hospital on risk of death and severe bleeding among patients with Covid-19.

Their findings are based on data from the United States Department of Veterans Affairs for 4,297 patients (average age 68 years; 93% men) admitted to hospital with Covid-19 between 1 March and 31 July 2020. Other potentially important factors including age, ethnicity, underlying conditions, medication history, weight, and smoking status were taken into account. The researchers then followed these patients to see who died or experienced a serious bleeding event within 30 days of hospital admission.

A total of 3,627 (84.4%) of patients received prophylactic anticoagulation within 24 hours of admission and there were 622 deaths (14.5%) within 30 days. Death at 30 days was 14.3% among those who received prophylactic anticoagulation compared with 18.7% among those who did not - a relative risk reduction as high as 34% and an absolute risk reduction of 4.4%. This benefit seemed to be greater among patients not admitted to the intensive care unit (ICU) within 24 hours of hospital admission. Receiving prophylactic anticoagulation was not associated with an increased risk of serious bleeding.

This was a large, well-designed study using electronic health record data and took account of a range of potentially influential factors. Results were also unchanged after further analyses, suggesting that they withstand scrutiny. However, the researchers acknowledge that due to the observational nature of the study, a degree of uncertainty persists that can only be addressed through randomised trials. Until further trial evidence is available, they conclude that these findings “provide strong real world evidence to support guidelines recommending the use of prophylactic anticoagulation as initial treatment for patients with Covid-19 on hospital admission.”


Source: BMJ

12.02.2021

Read all latest stories

Related articles

Photo

News • Protein malformation

Covid-19: immune reaction may cause amyloid generation

In patients with serious and long-term Covid-19, disturbed blood coagulation is often observed. Now, Swedish researchers found a connection between harmful amyloid production and Covid-19 symptoms.

Photo

News • Covid-19 drug monitoring

Smart sensor to evaluate vaccine safety

A new study enables developers to determine vaccine safety via smart sensors that measure objective physiological parameters. This could end the reliance on subjective reports of study participants.

Photo

News • Thromboembolic misunderstandings

Covid-19, not vaccination, presents biggest blood clot risks

Researchers from the University of Oxford have announced the results of a study into thrombocytopenia (a condition with low platelet counts) and thromboembolic events (blood clots) following…

Related products

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Mass Spectrometry

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Shimadzu Europa GmbH
Siemens Healthineers – Sysmex CA-600 Systems

Hemostaseology

Siemens Healthineers – Sysmex CA-600 Systems

Siemens Healthineers
Siemens Healthineers – Sysmex CS-2500 System

Hemostaseology

Siemens Healthineers – Sysmex CS-2500 System

Siemens Healthineers
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Subscribe to Newsletter